Weekly docetaxel and estramustine in patients with hormonerefractory prostate cancer
| Autor: | L Hake, M Bolton, J Wendt, P Ledakis, Max Norvell, J Lynch, S Tarantolo, J Muhvic, R Hauke, M. Sitki Copur |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
medicine.medical_specialty Paclitaxel medicine.drug_class medicine.medical_treatment Urology Docetaxel Adenocarcinoma Antiandrogen Drug Administration Schedule Prostate cancer Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Aged 80 and over Chemotherapy Performance status business.industry Prostatic Neoplasms Hematology Middle Aged medicine.disease Survival Analysis Surgery Regimen Oncology Tolerability Estramustine Taxoids business medicine.drug |
| Zdroj: | Seminars in Oncology. 28:16-21 |
| ISSN: | 0093-7754 |
| DOI: | 10.1016/s0093-7754(01)90150-2 |
| Popis: | The combination of docetaxel and estramustine has exhibited synergistic activity both in prostate cancer cell lines and in patients with hormone-refractory prostate cancer (HRPC). Based on these promising preclinical and phase I/II data, we conducted a study of weekly docetaxel and estramustine in patients with metastatic HRPC and a poor performance status. A total of 30 patients received (1) a 3-day course of oral estramustine during weeks 1 and 2 of each 3-week cycle plus (2) docetaxel, 35 mg/m 2 intravenously on day 2 of weeks 1 and 2. The median number of cycles per patient was 5, ranging from 1 to 22. The median patient age was 74 years (range, 61 to 90 years), and the median baseline Karnofsky performance status was 60% (range, 50% to 80%). Twenty-three patients (76%) had a ≥50% decrease in serum prostate-specific antigen (PSA); 17 (56%) of these patients had a ≥75% decrease in PSA. Pain scores and performance status likewise improved in 70% of patients. Three complete responses and four partial responses were observed among 12 patients with measurable disease. Toxicities were primarily nonhematologic in nature, with the most common being grade 1 through 3 nausea, asthenia, diarrhea, and edema. Given the activity and tolerability of weekly docetaxel and estramustine in this study, this regimen appears to be more suitable than previously studied docetaxel/estramustine administration schedules for treating metastatic HRPC in elderly patients with a poor performance status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|